Latest Breaking News On - Edoxaban treatment - Page 1 : vimarsana.com

Daiichi Sankyo Europe GmbH: Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF)

Daiichi Sankyo Europe GmbH: Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Van mieghemWolfgang schiesslStefan seyfriedDaiichi sankyo europeDaiichi sankyoDaiichi sankyo europe gmbEuropean society of cardiology congressPisa university hospitalEuropean society of cardiologyAtrial fibrillation networkUniversity cardiology divisionUniversity of pisaEuropean heart rhythm association practicalSankyo europeEuropean societyModified frailty index

Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF)

Four-year follow-up data reinforces the consistent effectiveness and safety of treatment with edoxaban in patients with atrial fibrillation (AF)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Van mieghemStefan seyfriedWolfgang schiesslDaiichi sankyo europeDaiichi sankyo europe gmbDaiichi sankyoAtrial fibrillation networkEuropean society of cardiologyPisa university hospitalEuropean heart rhythm association practicalUniversity of pisaEuropean society of cardiology congressUniversity cardiology divisionSankyo europeEuropean societyModified frailty index

Daiichi Sankyo Europe: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation

(0) Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA

Noord hollandThe netherlandsWolfgang schiesslDaiichi sankyoGarth virginDaiichi sankyo europeDaiichi sankyo europe gmbEuropean heart rhythm associationAtrial fibrillation at university of amsterdamAffairs specialty medicines at daiichi sankyo europeAmsterdam university medical centersDaiichi sankyo groupPortfolio communicationsEdoxaban clinical research programmeSankyo europeCardiac electrophysiology

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation 04/26/2021 | 03:01am EDT Send by mail : Message : Required fields Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA

Noord hollandThe netherlandsDaiichi sankyoGarth virginDaiichi sankyo europeEuropean heart rhythm associationAtrial fibrillation at university of amsterdamAffairs specialty medicines at daiichi sankyo europeAmsterdam university medical centersDaiichi sankyo groupEdoxaban clinical research programmeCardiac electrophysiologyAtrial fibrillationEdoxaban treatmentSankyo groupPharma innovator